DE69428214D1 - Transformierender wachstumsfaktor alpha h1 - Google Patents

Transformierender wachstumsfaktor alpha h1

Info

Publication number: DE69428214D1
Authority: DE; Germany
Prior art keywords: alpha; polypeptide; growth factor; transforming growth; factor alpha
Prior art date: 1994-03-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

DE69428214T

Other languages

English (en)

Other versions

DE69428214T2 (de

Inventor

Paul S Meissner

Rebecca Fuldner

Mark D Adams

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Human Genome Sciences Inc

Original Assignee

Human Genome Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-03-08

Filing date

1994-05-12

Publication date

2001-10-11

1994-05-12 Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc

2001-10-11 Publication of DE69428214D1 publication Critical patent/DE69428214D1/de

2002-06-27 Application granted granted Critical

2002-06-27 Publication of DE69428214T2 publication Critical patent/DE69428214T2/de

2014-05-13 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 title 1
102000006747 Transforming Growth Factor alpha Human genes 0.000 title 1
101800004564 Transforming growth factor alpha Proteins 0.000 title 1
229920001184 polypeptide Polymers 0.000 abstract 5
108090000765 processed proteins & peptides Proteins 0.000 abstract 5
102000004196 processed proteins & peptides Human genes 0.000 abstract 5
239000005557 antagonist Substances 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
230000001225 therapeutic effect Effects 0.000 abstract 2
101500027527 Homo sapiens Transforming growth factor alpha Proteins 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
239000008024 pharmaceutical diluent Substances 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1
238000010188 recombinant method Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Toxicology (AREA)
Immunology (AREA)
Wood Science & Technology (AREA)
Endocrinology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Urology & Nephrology (AREA)
Crystallography & Structural Chemistry (AREA)
Ophthalmology & Optometry (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DE69428214T 1994-03-08 1994-05-12 Transformierender wachstumsfaktor alpha h1 Expired - Fee Related DE69428214T2 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/208,008 US5633147A (en)	1994-03-08	1994-03-08	Transforming growth factor αH1
PCT/US1994/005476 WO1995024466A1 (en)	1994-03-08	1994-05-12	Transforming growth factor alpha h1

Publications (2)

Publication Number	Publication Date
DE69428214D1 true DE69428214D1 (de)	2001-10-11
DE69428214T2 DE69428214T2 (de)	2002-06-27

Family

ID=22772852

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69428214T Expired - Fee Related DE69428214T2 (de)	1994-03-08	1994-05-12	Transformierender wachstumsfaktor alpha h1

Country Status (14)

Country	Link
US (1)	US5633147A (de)
EP (2)	EP1063293A3 (de)
JP (1)	JPH09509846A (de)
KR (1)	KR970701776A (de)
CN (1)	CN1087344C (de)
AT (1)	ATE205254T1 (de)
AU (1)	AU681406B2 (de)
CA (1)	CA2184583A1 (de)
DE (1)	DE69428214T2 (de)
DK (1)	DK0759067T3 (de)
ES (1)	ES2161246T3 (de)
PT (1)	PT759067E (de)
WO (1)	WO1995024466A1 (de)
ZA (1)	ZA943465B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6608182B1 (en) *	1994-03-08	2003-08-19	Human Genome Sciences, Inc.	Human vascular endothelial growth factor 2
US7109308B1 (en)	1994-03-08	2006-09-19	Human Genome Sciences, Inc.	Antibodies to human vascular endothelial growth factor 2
US20020188110A1 (en) *	1994-03-08	2002-12-12	Human Genome Sciences, Inc.	Transforming growth factor alpha HI
US6074839A (en) *	1994-03-08	2000-06-13	Human Genome Sciences, Inc.	Transforming growth factor αHI
US7153827B1 (en) *	1994-03-08	2006-12-26	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2 and methods of use
US7186688B1 (en)	1994-03-08	2007-03-06	Human Genome Sciences, Inc.	Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
ATE309360T1 (de) *	1994-03-08	2005-11-15	Human Genome Sciences Inc	Vaskularer endothelialer wachstumsfaktor 2
US6734285B2 (en)	1994-03-08	2004-05-11	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2 proteins and compositions
US6040157A (en) *	1994-03-08	2000-03-21	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US5932540A (en)	1994-03-08	1999-08-03	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US6030613A (en)	1995-01-17	2000-02-29	The Brigham And Women's Hospital, Inc.	Receptor specific transepithelial transport of therapeutics
US6410506B1 (en)	1995-05-19	2002-06-25	Human Genome Sciences, Inc.	Transforming growth factor α HII
US8212004B2 (en)	1999-03-02	2012-07-03	Human Genome Sciences, Inc.	Neutrokine-alpha fusion proteins
US6812327B1 (en)	1996-10-25	2004-11-02	Human Genome Sciences, Inc.	Neutrokine-alpha polypeptides
US7294482B2 (en) *	1998-11-19	2007-11-13	Millennium Pharmaceuticals, Inc.	EGF-like nucleic acids
WO2000029438A1 (en) *	1998-11-19	2000-05-25	Millennium Pharmaceuticals, Inc.	Egf-like nucleic acids and polypeptides and uses thereof
US7223724B1 (en) *	1999-02-08	2007-05-29	Human Genome Sciences, Inc.	Use of vascular endothelial growth factor to treat photoreceptor cells
US20020099008A1 (en) *	1999-04-26	2002-07-25	Daniel R. Twardzik	Method for stimulating hematopoiesis using tgf-alpha
ATE364315T1 (de) *	1999-04-26	2007-07-15	Applied Protein Sciences Llc	Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung
US20020193301A1 (en)	1999-08-19	2002-12-19	Stem Cell Pharmaceuticals, Inc.	TGF-alpha polypeptides, functional fragments and methods of use therefor
WO2001012127A2 (en) *	1999-08-19	2001-02-22	Stem Cell Pharmaceuticals, Inc.	TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
US7879328B2 (en)	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
CA2407910C (en)	2000-06-16	2013-03-12	Steven M. Ruben	Antibodies that immunospecifically bind to blys
NZ518077A (en) *	2000-08-04	2003-11-28	Human Genome Sciences Inc	Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
US20030091565A1 (en)	2000-08-18	2003-05-15	Beltzer James P.	Binding polypeptides and methods based thereon
GB0020953D0 (en) *	2000-08-24	2000-10-11	Smithkline Beecham Biolog	Vaccine
US20030170786A1 (en) *	2001-04-13	2003-09-11	Rosen Craig A.	Vascular endothelial growth factor 2
WO2002083704A1 (en) *	2001-04-13	2002-10-24	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US7402312B2 (en) *	2001-04-13	2008-07-22	Human Genome Sciences, Inc.	Antibodies to vascular endothelial growth factor 2 (VEGF-2)
WO2002083849A2 (en) *	2001-04-13	2002-10-24	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US20050232921A1 (en) *	2001-04-13	2005-10-20	Rosen Craig A	Vascular endothelial growth factor 2
WO2004089357A2 (en) *	2003-04-02	2004-10-21	Regents Of The University Of Minnesota	Anti-fungal formulation of triterpene and essential oil
US9168286B2 (en)	2005-10-13	2015-10-27	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
US8211649B2 (en)	2006-03-31	2012-07-03	Human Genome Sciences, Inc.	Methods of diagnosing and prognosing hodgkin's lymphoma
KR101622412B1 (ko) *	2007-10-19	2016-05-18	제넨테크, 인크.	시스테인 조작된 항-ｔｅｎｂ２ 항체 및 항체 약물 접합체

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI890312A (fi) *	1988-01-25	1989-07-26	Oncogen	Amfiregulin: ett nytt bifunktionellt tillvaext modulerande glykoprotein.
US5115096A (en) *	1988-04-15	1992-05-19	Oncogen	Amphiregulin: a bifunctional growth modulating glycoprotein
US5256643A (en) *	1990-05-29	1993-10-26	The Government Of The United States	Human cripto protein

1994
- 1994-03-08 US US08/208,008 patent/US5633147A/en not_active Expired - Lifetime
- 1994-05-12 DK DK94916791T patent/DK0759067T3/da active
- 1994-05-12 DE DE69428214T patent/DE69428214T2/de not_active Expired - Fee Related
- 1994-05-12 CA CA002184583A patent/CA2184583A1/en not_active Abandoned
- 1994-05-12 AU AU68350/94A patent/AU681406B2/en not_active Ceased
- 1994-05-12 JP JP7523424A patent/JPH09509846A/ja not_active Ceased
- 1994-05-12 AT AT94916791T patent/ATE205254T1/de not_active IP Right Cessation
- 1994-05-12 PT PT94916791T patent/PT759067E/pt unknown
- 1994-05-12 KR KR1019960704894A patent/KR970701776A/ko not_active Application Discontinuation
- 1994-05-12 EP EP00120470A patent/EP1063293A3/de not_active Withdrawn
- 1994-05-12 ES ES94916791T patent/ES2161246T3/es not_active Expired - Lifetime
- 1994-05-12 WO PCT/US1994/005476 patent/WO1995024466A1/en active IP Right Grant
- 1994-05-12 CN CN94195051A patent/CN1087344C/zh not_active Expired - Fee Related
- 1994-05-12 EP EP94916791A patent/EP0759067B1/de not_active Expired - Lifetime
- 1994-05-19 ZA ZA943465A patent/ZA943465B/xx unknown

Also Published As

Publication number	Publication date
EP1063293A2 (de)	2000-12-27
EP0759067A1 (de)	1997-02-26
PT759067E (pt)	2002-02-28
EP1063293A3 (de)	2001-07-11
JPH09509846A (ja)	1997-10-07
WO1995024466A1 (en)	1995-09-14
EP0759067B1 (de)	2001-09-05
DK0759067T3 (da)	2001-10-22
EP0759067A4 (de)	1997-10-22
AU681406B2 (en)	1997-08-28
ZA943465B (en)	1995-11-20
ATE205254T1 (de)	2001-09-15
US5633147A (en)	1997-05-27
DE69428214T2 (de)	2002-06-27
KR970701776A (ko)	1997-04-12
CA2184583A1 (en)	1995-09-14
ES2161246T3 (es)	2001-12-01
CN1087344C (zh)	2002-07-10
CN1143386A (zh)	1997-02-19
AU6835094A (en)	1995-09-25

Legal Events

Date	Code	Title
2002-04-04	8332	No legal effect for de
2002-04-18	8370	Indication related to discontinuation of the patent is to be deleted
2002-10-02	8364	No opposition during term of opposition
2007-03-15	8339	Ceased/non-payment of the annual fee

Publication	Publication Date	Title
DE69428214D1 (de)	2001-10-11	Transformierender wachstumsfaktor alpha h1
DK0751992T3 (da)	2006-03-06	Karendotelvækstfaktor 2
HUP0103758A2 (hu)	2002-01-28	Neurotróf faktorok
PT735818E (pt)	2004-07-30	Proteinas inflamatorias de macrofagos pim-3 pim-4 e pim-1y
GB9224584D0 (en)	1993-01-13	Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
EP0787802A3 (de)	1997-08-27
ATE358176T1 (de)	2007-04-15	Menschliche dnase
DK1165791T3 (da)	2008-02-11	Humant cytokin som zalpha-receptor-ligand og anvendelse deraf
AU1724795A (en)	1996-07-03	Human tissue inhibitor of metalloproteinase-4
DK0669979T3 (da)	2006-03-06	C-C CKR-1, kemokinreceptor
EP0825996A4 (de)	2000-06-14	Dem fibroblasten wachstumsfaktor homologer faktor-1(fhf-1) und methoden zu seiner verwendung
DE3881023D1 (de)	1993-06-17	Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
NZ335633A (en)	2000-10-27	Production of recombinant H. pylori polypeptides for treatment and diagnosis of H. pylori related diseases
ATE119914T1 (de)	1995-04-15	Peptide, deren verwendung als immuno- suppressanten und verfahren zu deren herstellung.
NO890174L (no)	1989-07-17	Rekombinante interleukin-1alfa-polypeptider.
WO1996009391A3 (en)	1996-08-29	Dna sequence and protein of the non-structural reading frame i of the human parvovirus b19
WO2003014293A3 (en)	2003-12-24	Novel polypeptide analogs and fusions and their methods of use
EP0780472A3 (de)	1998-05-20	Stress Proteine
AU2459188A (en)	1989-05-04	Anticoagulative protein pp4-x, and its preparation and use
ATE229983T1 (de)	2003-01-15	Maspin- ein neues serpin mit tumor unterdrückender aktivität
EP0832109A4 (de)	2000-06-14	Faktor-2, homolog zum fibroblasten-wachstumsfaktor und verfahren zu seiner anwendung
DE68917520D1 (de)	1994-09-22	Verfahren und Systeme zur Herstellung von HIV-Antigenen.
WO2001075008A3 (fr)	2002-02-07	Nouveau polypeptide, protéine hélicase-anneau-hélicase 11, et polynucleotide codant pour ce polypeptide
WO2001068693A8 (fr)	2001-11-01	Nouveau polypeptide, proteine humaine de reception cannabinoide 7, et polynucleotide codant pour ce polypeptide
WO2001075010A3 (fr)	2002-03-07	Nouveau polypeptide, proteine humaine de transduction nucleaire 25 contenant un domaine structurel atp/gtp, et polynucleotide codant pour ce polypeptide